阿托伐他汀联合替米沙坦治疗特发性阵发性心房颤动  

Study on the curative effect of Atorvastatin combined with Telmisartan on Idiopathic paroxysmal atrial fibrillation

作　　者：陈绍奉 安维哨 薛盛龙 徐上淼 缪克强 王俊道 

机构地区：[1]浙江省苍南县第二人民医院心血管内科,325802

出　　处：《中国基层医药》2012年第2期177-178,共2页Chinese Journal of Primary Medicine and Pharmacy

基　　金：浙江省苍南县科技计划项目（2009S35）

摘　　要：目的观察阿托伐他汀联合替米沙坦治疗特发性阵发性心房颤动的疗效。方法将70例特发性阵发性心房颤动患者随机分为观察组与对照组各35例。观察组采用阿托伐他汀联合替米沙坦治疗，对照组单用替米沙坦治疗，治疗并随访半年，对比观察两组患者疗效，分析两组患者用药前后血浆C反应蛋白（CRP）和心律失常发作情况。结果治疗后患者症状均有不同程度改善，观察组有效率（88．6％）显著高于对照组（68．6％），CRP含量显著低于对照组（均P〈0．05）。结论阿托伐他汀联合替米沙坦治疗特发性阵发性心房颤动优于单一替米沙坦治疗，能较好改善临床症状。Objective To investigate the clinical efficacy of Telmisartan combined with Atorvastatin in treating patients with idiopathic paroxysmal atrial fibrillation（IPAF）. Methods 70 cases of IPAF were randomly divided into study group （given treatment of Telmisartan combined with Atorvastatin） and control group （given treatment of Telmisartan） ,35 cases in each group,all patients got 2 years follow-up visit. The change of CRP and the arrhythmia recurrence were observed after treatment. Results After surgery, patients were better than before, but the efficiency in study group was significantly higher than control group （ 88.6% vs 68.6%, P 〈 0.05 ） ; CRP of the two groups were significantly reduced after treatment, two groups have significant difference （ P 〈 0.05 ）. Conclusion Curative effect of atorvastatin combined with telmisartan on IPAF is better than that of telmisartan treatment and clinical implementation should be promoted.

关 键 词：心房颤动 阿托伐他汀 替米沙坦 C反应蛋白 

分 类 号：R541.75[医药卫生—心血管疾病]